Categories
Change Password!
Reset Password!
Age was found to be a
significant factor affecting the elimination of neutralizing antibodies in
healthy people receiving the BNT162b2 mRNA vaccine.
A prospective study reported a persistent but declining anti-COVID humoral immunity at 6 months after complete vaccination with BNT162b2 mRNA in healthy people. However, it was more significant among older persons. Researchers aimed to determine neutralizing antibodies (Nabs) kinetics against coronavirus up to 6 months following 2nd dose of BNT162b2 vaccine.
Estimation of Nabs levels was done on days 1 (prior to the 1st vaccine shot), 8, 22 (prior to the 2nd shot), 36, 50, and three and six months following the 2nd vaccination. The study incorporated 308 healthy participants without malignant disease. At 6 months, the percentage of people with Nabs values less than 30%, less than 50%, and more than 75% are shown in Table 1:
Elimination of Nabs was found to be biphasic. Initially, Nabs were eliminated at a relatively slower rate. However, after 3 months, Nabs elimination was 5.7 times higher. At all the evaluated time points, older age was inversely linked with Nabs levels. According to the estimation of a population modeling assessment, about half of the people will have Nabs titers less than 73.8% and 64.6% at nine and twelve months, respectively, after complete vaccination.
Thus, the findings of the study offered pivotal insights into the timing of robust booster vaccinations, that might be age-dependent.
Life
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals
Evangelos Terpos et al.
Comments (0)